A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
2022-06-27
عنوان الدراسة
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors
داعم الدراسة
Novartis
دواء الدراسة
ABL001 (asciminib)
رقم بروتوكول الدراسة
CABL001A2301
حالة الدراسة
Ongoing
موقع الدراسة
KFSH&RC-R
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.